Eltromin Tablet 25 mg is a prescription medication containing Eltrombopag Olamine, a thrombopoietin receptor agonist used to treat conditions associated with low platelet counts (thrombocytopenia). It is primarily prescribed for patients with chronic immune thrombocytopenia (ITP), aplastic anemia, or thrombocytopenia due to hepatitis C therapy, where increasing platelet counts is crucial to reduce bleeding risks.

Eltrombopag works by stimulating the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors in the bone marrow, promoting their proliferation and differentiation into platelets. This targeted mechanism allows patients to achieve improved platelet counts without directly transfusing platelets, thereby enhancing hemostatic function and reducing the risk of bleeding complications.

Eltromin is particularly valuable for patients who have not responded adequately to conventional therapies such as corticosteroids, immunoglobulins, or splenectomy. By supporting endogenous platelet production, it helps maintain safe platelet levels and improves quality of life in individuals with chronic low platelet counts.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Hematopoietic Agent

• Thrombopoietin Receptor Agonist

Composition

Each tablet contains:

• Eltrombopag Olamine: 25 mg

This dosage is tailored to provide effective platelet stimulation while allowing for safe titration based on patient response.

Indications

Eltromin Tablet 25 mg is indicated for:

• Chronic immune thrombocytopenia (ITP) in adults and children who have not responded adequately to standard therapies

• Thrombocytopenia associated with chronic hepatitis C, to allow the initiation or maintenance of interferon-based therapy

• Severe aplastic anemia in patients with insufficient response to immunosuppressive therapy

It is used under close supervision by a hematologist or specialist in blood disorders.

Mechanism of Action

Eltrombopag acts as a thrombopoietin receptor agonist:

• Binds to the c-Mpl receptor on megakaryocyte progenitor cells in the bone marrow

• Stimulates proliferation and differentiation of these precursors into mature platelets

• Enhances platelet production, thereby improving hemostasis and reducing bleeding risks

Unlike platelet transfusions, Eltrombopag supports endogenous platelet production, offering a more sustainable and physiological approach to managing thrombocytopenia.

Dosage and Administration

• Initial dose: 25 mg once daily, taken orally

• Tablets should be taken on an empty stomach, at least 1 hour before or 2 hours after meals

• Dose adjustments are made based on platelet response and patient tolerance

• Regular monitoring of platelet counts, liver function tests, and blood parameters is required

• Avoid abrupt discontinuation; tapering may be advised in consultation with a physician

Possible Side Effects

Eltromin is generally well tolerated, but potential side effects may include:

• Headache

• Fatigue

• Nausea or vomiting

• Abdominal discomfort

• Elevated liver enzymes

• Rarely, thromboembolic events due to excessively high platelet counts

Patients should promptly report any unusual bruising, bleeding, or signs of clot formation.

Precautions and Warnings

• Use cautiously in patients with liver impairment or history of thromboembolic events

• Monitor liver function and platelet counts regularly

• Avoid concurrent use with other medications that increase bleeding or clotting risk without physician guidance

• Pregnancy and breastfeeding: use only if clearly indicated and under medical supervision

• Not suitable for patients with known hypersensitivity to Eltrombopag

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store below 30°C in a dry place

• Protect from moisture and light

• Keep out of reach of children.